What Actually Gets Prescribed and What Doesn't
I went through about four years of patients asking me about weight loss medications before I stopped trying to keep a mental list straight. The landscape shifts every few months anyway. There are injectables now that didn't exist when I started paying attention, and then there are the over-the-counter supplements sitting on store shelves that are a completely different category entirely. People conflate them constantly, and it matters because the risk profiles are wildly different. The FDA-approved prescription options fall into a few families. GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are the big ones right now. They slow gastric emptying and target appetite centers in the brain. Liraglutide (Saxenda) is the older version of the same class. Then there's phentermine-topiramate (Qsymia), bupropion-naltrexone (Contrave), and orlistat (Xenical, Allside). Phendimetrazine and diethylpropion are older stimulants you'll occasionally see, though they carry more cardiovascular concerns. Each one has its own mechanism, which means side effect profiles diverge significantly. The supplements on the other hand — garcinia cambogia, green tea extract, CLA, raspberry ketones — have almost no meaningful clinical evidence behind them. Some have shown trivial effects in tiny studies that don't replicate at scale. The supplement industry operates under DSHEA regulations, which means the FDA doesn't approve them for safety or efficacy before they hit the shelf. That's not a casual distinction. It's the difference between a drug that went through Phase III trials and something whose purity and dosage are essentially self-reported by the manufacturer.
Navigating Diet Pills On The Market
Here's how the prescription side actually works in practice. A patient comes in with a BMI over 30, or over 27 with a comorbidity like hypertension or type 2 diabetes. The clinician orders baseline labs — metabolic panel, lipids, HbA1c, thyroid function — because you need a starting point and you need to rule out secondary causes. If they qualify, you discuss which medication fits their profile. Semaglutide is first-line for most people now unless there's a contraindication. The key thing nobody tells you is that the dose escalates slowly over about sixteen weeks before reaching the therapeutic level. Rushing that schedule doesn't improve outcomes, it just increases the likelihood of gastrointestinal side effects, which is where most people bail. For over-the-counter products, the process is almost the opposite of anything medical. You're looking at third-party testing certifications — USP Verified, NSF Certified, Informed-Choice — because without those marks you're buying whatever the label says, and labels are unreliable. I've seen products test positive for undeclared stimulants, heavy metals, or ingredients completely absent from the ingredient list. One specific case: a client bought a "natural metabolism booster" that tested clean on paper but contained synephrine at three times the labeled dose, probably from batch contamination. He had tachycardia and anxiety spikes that resolved after he stopped. I had him verify that particular brand's latest batch analysis before he'd ever buy from them again. Randomize your sourcing or don't bother. One thing people consistently miss is that diet pills aren't a substitution for fundamentals, they're an adjunct. The weight loss pharmacology is modest at best even under ideal conditions. Semaglutide averages about fifteen to twenty percent body weight reduction in clinical trials over sixty-eight weeks. That's meaningful, but it's not magic, and it requires caloric deficit maintenance. When people stop the medication, the weight tends to return because the appetite suppression is gone. I've seen patients gain back the majority of lost weight within a year of discontinuation. That's not a failure of the drug, it's a feature of how the biology works. These medications manage a chronic condition rather than cure it, the same way antihypertensives work.
Counter-intuitively, the older stimulants like phentermine sometimes produce more sustained weight loss in real-world settings than the newer agents for a subset of patients. Not because they're better, but because they're cheaper, more accessible, and patients stay on them longer. Insurance covers phentermine in most cases. GLP-1 agonists frequently face prior authorization battles, stock shortages, and copays that range from nothing to thousands per month depending on the plan. That access friction changes adherence patterns in ways the trial data doesn't capture. If you're considering any of these options, the practical first step is a conversation with someone who can evaluate whether you actually qualify and which mechanism aligns with your health profile. Self-prescribing from international websites is common and dangerous — I've treated complications from unprescribed semaglutide sourced through unregulated channels, and the product quality was unpredictable. Compounded versions exist in a gray area that shifts with FDA enforcement priorities. The risks are real and they're not theoretical.
Get the Full Details
